![Anabella Villalobos](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 50 100 $ in data 30/09/2026
Dr. Anabella Villalobos is an Independent Director at Coya Therapeutics, Inc. She is on the Board of Directors at Coya Therapeutics, Inc. Dr. Villalobos was previously employed as a SVP-Biotherapeutics & Medicinal Sciences by Biogen, Inc. and a Vice President by Pfizer Inc. She received her undergraduate degree from the University of Panama and a doctorate degree from the University of Kansas.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 01/05/2026 | 10.000 ( 0,04% ) | 50 100 $ | 30/09/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| COYA THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 25/05/2021 |
| Società | Posizione | Fine |
|---|---|---|
| BIOGEN INC. | Corporate Officer/Principal | 01/01/2025 |
| PFIZER INC. | Corporate Officer/Principal | 01/01/2017 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 5 |
|---|---|
Pfizer Inc.
 Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
University of Kansas
 University of Kansas Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Panama
 University of Panama Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Coya Therapeutics, Inc.
 Coya Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that focuses on research and development of therapies to enhance the function of regulatory T cells | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
